NCT04374994

Daily Avanafil for Erectile Dysfunction

Evaluation of the Clinical and Molecular Efficacy of Daily Avanafil in Egyptian Males With Erectile and Endothelial Dysfunction (Randomized Placebo-Controlled Study)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: University of Alexandria · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, the investigators tried to study the effect of daily avanafil on the serum level of endothelial function markers, as well as its impact on the erectile function in males with erectile and endothelial dysfunction by comparing the results with controls who received placebo.

Detailed description

Avanafil is a highly selective and potent oral phosphodiesterase type 5 inhibitor (PDE5-I) . However, its impact on the soluble markers of endothelial function has not been investigated yet. This study was conducted to assess the effect of daily avanafil on the erectile function and endothelial markers' serum level. In this work we recruited males with erectile dysfunction and other diseases commonly associated with endothelial dysfunction. The investigators randomly treated patients with daily oral avanafil and the other patients with placebo. The investigators measured the International Index of Erectile Function -5 score (IIEF- 5) and the serum levels of markers of endothelial function at baseline and treatment.

Conditions

• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	Avanafil 50 MG	Oral phosphodiesterase type 5 inhibitors
DRUG	Placebo oral tablet	lactose and maize starch, Egypt

Timeline

• Start date: 2018-09-01
• Primary completion: 2019-04-15
• Completion: 2019-10-10
• First posted: 2020-05-05
• Last updated: 2020-09-16

Locations

1 site across 1 country: Egypt